Back to resultsUse of Botulinum Toxin in the Treatment of Androgenic Alopecia
Primary Purpose
Androgenetic Alopecia
Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
incobotulinumtoxin A
Sponsored by
About this trial
This is an interventional treatment trial for Androgenetic Alopecia
Eligibility Criteria
Inclusion Criteria:
- Subjects must be diagnosed by the investigator with mild to moderate degree of hair-pattern loss (androgenic alopecia). Mild to moderate will be defined by investigator assessment of III Vertex-V on the Norwood Scale ( for males) or 3-6 on the Savin Scale (for females).
- Subjects must be between 22-45 years of age with mild to moderate AGA with no known medical conditions that, in the investigator's opinion, may interfere with study participation.
- Subjects must agree to maintain the same hair grooming and style routine during study participation.
- Sexually active females of childbearing potential participating in the study must agree to use a medically-acceptable method of contraception while receiving study product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses. Exception: Sexually inactive females of childbearing potential are not required to practice a reliable method of contraception and may be enrolled at the investigator's discretion, provided that they understand the possible risks involved in getting pregnant during the study and are counseled to remain sexually inactive for the duration of the study or to practice a reliable method of contraception if becoming sexually active during the study.
- Subjects must sign a written informed consent.
- Subjects must sign a photo release form.
Exclusion Criteria:
- Any systemic treatment for hair loss within the last 6 months including hormonal therapy for peri-menopausal females.
- Concurrent therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study.
- Subjects under current treatments in study area with light therapy, microneedling, Platelet-rich Plasma, prostaglandin analogues, ketoconazole, hair transplant or any method deemed unacceptable by the investigator.
- Any history of drug interaction, such as, aminoglycoside antibiotics, penicillamine, quinine and calcium channel blockers
- Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products.
- History of allergic reaction to similar products (Botox® or Dysport®)
- Albumin sensitivity (allergy to eggs)
- Subjects with any signs of infection at the injection sites
- Active cold or sinus infection
- Any dermatologic or systemic disorder, which in the investigator's opinion, may interfere with the treatment. Examples of such disorders include neuromuscular disorders, hypertrophic scarring, keloidal scarring, bleeding disorders, subjects on immunosuppressive medications, and lupus erythematosus.
- Subjects who are pregnant, breast feeding or planning a pregnancy during the study period.
- Subjects who are unwilling or unable to comply with the requirements of the protocol.
- Participation in another research study (currently or within the last 30 days).
- All volunteers unwilling to sign the consent forms after being informed of their obligations and risks that they might encounter as a participant in this study.
Sites / Locations
- ZelSkin and Laser SpecialistsRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Single treatment with Xeomin® (incobotulinumtoxin A)
Arm Description
Individual balding scalps will be outlined and mapped to include up to 30 injection sites evenly distributed within the hair loss area. At each site, 5 Units of Xeomin® will be injected with a maximum of 150 Units total per subject. This will be a single, one-time treatment session.
Outcomes
Primary Outcome Measures
Changes from baseline in hair count per cm2 (number of hairs per follicular unit)
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline hair count per cm2 will be compared to day 30, day 90, day 180 and day 270.
Changes from baseline in sum of hair width per cm2 (total scalp coverage)
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline sum of hair width per cm2 will be compared to day 30, day 90, day 180 and day 270.
Changes from baseline in Terminal:Vellus ratio (number of terminal hairs for every one vellus hair).
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline Terminal:Vellus ratio will be compared to day 30, day 90, day 180 and day 270.
Changes from baseline in Average hairs per follicular unit (average number of hairs within a hair follicle).
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline average hairs per follicular unit will be compared to day 30, day 90, day 180 and day 270.
Changes from baseline in Average hair width (microns) (average thickness of hair in microns).
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline average hair width (microns) will be compared to day 30, day 90, day 180 and day 270.
Changes from baseline in Follicle count per cm2 (number of follicles per square centimeter).
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline follicle count per cm2 will be compared to day 30, day 90, day 180 and day 270.
Mean Inter-follicular distance (mm) (mean distance between follicular units).
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline mean inter-follicular distance (mm) will be compared to day 30, day 90, day 180 and day 270.
Secondary Outcome Measures
Change from baseline in balding scalp hair recovery assessed by study investigator
Hair recovery will be assessed by the study investigator on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Change from baseline in balding scalp hair recovery assessed by study investigator
Hair recovery will be assessed by the study investigator on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Change from baseline in balding scalp hair recovery assessed by study investigator
Hair recovery will be assessed by the study investigator on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Change from baseline in balding scalp hair recovery assessed by study investigator
Hair recovery will be assessed by the study investigator on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Change from baseline in balding scalp hair recovery assessed by study participant
Hair recovery will be assessed by the study participant on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Change from baseline in balding scalp hair recovery assessed by study participant
Hair recovery will be assessed by the study participant on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Change from baseline in balding scalp hair recovery assessed by study participant
Hair recovery will be assessed by the study participant on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Change from baseline in balding scalp hair recovery assessed by study participant
Hair recovery will be assessed by the study participant on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Full Information
NCT ID
NCT05456087
First Posted
April 12, 2022
Last Updated
October 3, 2022
Sponsor
Zel Skin and Laser Specialists
Collaborators
Merz Aesthetics Inc.
1. Study Identification
Unique Protocol Identification Number
NCT05456087
Brief Title
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
Official Title
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 12, 2022 (Actual)
Primary Completion Date
July 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zel Skin and Laser Specialists
Collaborators
Merz Aesthetics Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the effect of using a purified botulinum toxin (Xeomin®, Merz, USA), the same injectable used to improve face wrinkles, to treat a specific type of hair loss seen in men and women not associated with scarring or other internal disease called 'pattern hair loss'. This type of hair loss is medically called 'androgenic or androgenetic alopecia'. In men it is typically called 'male pattern baldness' whereas in women it is called 'female pattern baldness' and in both cases is hereditary meaning there will be a history of relatives that describe having the same condition.
Detailed Description
Adult volunteers aged 22-45 years presenting with mild to moderate patterned hair loss will be screened for participation. Twenty subjects (10 males and 10 females) meeting the inclusion/exclusion criteria will be recruited to participate. Prior to any injections a global photograph documenting the patterned hair loss will be acquired for each individual utilizing the Canfield global camera system. Each subject will then undergo trichoscopy imaging within the defined treatment area using the Canfield HairMetrix® system. The imaged area is at a higher magnification capable of reliable measurements for hair density (count/cm2), hair shaft diameter, follicular units, among other measurements captured by the software. Individual balding scalps will be outlined and mapped to include up to 30 injection sites evenly distributed within the hair loss area.
At each site, 5 Units of Xeomin® will be injected with a maximum of 150 Units total per subject. This will be a single, one-time treatment session. Consequently, subjects will be contacted by phone or will be asked to come into the clinic for follow up according to a set schedule.
At each follow up visit (monthly) subjects will be asked to report any adverse events. Follow up visits at the clinic will also include photographic documentation, trichoscopy, and investigator and subject subjective reporting of treatment progress.
There will be a total of up to 3 injectors, 1 person taking photographs (including trichoscopy), and 1 investigator assessing treatment outcome.
During this 9 month-long study, subjects cannot utilize other hair loss treatments and must maintain their grooming routine which includes maintaining their hair style.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Androgenetic Alopecia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Single treatment with Xeomin® (incobotulinumtoxin A)
Arm Type
Experimental
Arm Description
Individual balding scalps will be outlined and mapped to include up to 30 injection sites evenly distributed within the hair loss area. At each site, 5 Units of Xeomin® will be injected with a maximum of 150 Units total per subject. This will be a single, one-time treatment session.
Intervention Type
Drug
Intervention Name(s)
incobotulinumtoxin A
Other Intervention Name(s)
Xeomin
Intervention Description
Up to 150 units of incobotulinumtoxin A will be injected at up to 30 injection sites within the hair loss area
Primary Outcome Measure Information:
Title
Changes from baseline in hair count per cm2 (number of hairs per follicular unit)
Description
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline hair count per cm2 will be compared to day 30, day 90, day 180 and day 270.
Time Frame
Day 30, Day 90, Day 180, and Day 270
Title
Changes from baseline in sum of hair width per cm2 (total scalp coverage)
Description
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline sum of hair width per cm2 will be compared to day 30, day 90, day 180 and day 270.
Time Frame
Day 30, Day 90, Day 180, and Day 270
Title
Changes from baseline in Terminal:Vellus ratio (number of terminal hairs for every one vellus hair).
Description
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline Terminal:Vellus ratio will be compared to day 30, day 90, day 180 and day 270.
Time Frame
Day 30, Day 90, Day 180, and Day 270
Title
Changes from baseline in Average hairs per follicular unit (average number of hairs within a hair follicle).
Description
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline average hairs per follicular unit will be compared to day 30, day 90, day 180 and day 270.
Time Frame
Day 30, Day 90, Day 180, and Day 270
Title
Changes from baseline in Average hair width (microns) (average thickness of hair in microns).
Description
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline average hair width (microns) will be compared to day 30, day 90, day 180 and day 270.
Time Frame
Day 30, Day 90, Day 180, and Day 270
Title
Changes from baseline in Follicle count per cm2 (number of follicles per square centimeter).
Description
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline follicle count per cm2 will be compared to day 30, day 90, day 180 and day 270.
Time Frame
Day 30, Day 90, Day 180, and Day 270
Title
Mean Inter-follicular distance (mm) (mean distance between follicular units).
Description
Trichoscopy equipped with Canfield HairMetrix® software system will be performed on the scalp of study participants. The baseline mean inter-follicular distance (mm) will be compared to day 30, day 90, day 180 and day 270.
Time Frame
Day 30, Day 90, Day 180, and Day 270
Secondary Outcome Measure Information:
Title
Change from baseline in balding scalp hair recovery assessed by study investigator
Description
Hair recovery will be assessed by the study investigator on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Time Frame
Day 30
Title
Change from baseline in balding scalp hair recovery assessed by study investigator
Description
Hair recovery will be assessed by the study investigator on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Time Frame
Day 90
Title
Change from baseline in balding scalp hair recovery assessed by study investigator
Description
Hair recovery will be assessed by the study investigator on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Time Frame
Day 180
Title
Change from baseline in balding scalp hair recovery assessed by study investigator
Description
Hair recovery will be assessed by the study investigator on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Time Frame
Day 270
Title
Change from baseline in balding scalp hair recovery assessed by study participant
Description
Hair recovery will be assessed by the study participant on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Time Frame
Day 30
Title
Change from baseline in balding scalp hair recovery assessed by study participant
Description
Hair recovery will be assessed by the study participant on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Time Frame
Day 90
Title
Change from baseline in balding scalp hair recovery assessed by study participant
Description
Hair recovery will be assessed by the study participant on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Time Frame
Day 180
Title
Change from baseline in balding scalp hair recovery assessed by study participant
Description
Hair recovery will be assessed by the study participant on a 4- point scale, where 0 is poor and 3 is excellent. Photographic documentation will be utilized.
Time Frame
Day 270
10. Eligibility
Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects must be diagnosed by the investigator with mild to moderate degree of hair-pattern loss (androgenic alopecia). Mild to moderate will be defined by investigator assessment of III Vertex-V on the Norwood Scale ( for males) or 3-6 on the Savin Scale (for females).
Subjects must be between 22-45 years of age with mild to moderate AGA with no known medical conditions that, in the investigator's opinion, may interfere with study participation.
Subjects must agree to maintain the same hair grooming and style routine during study participation.
Sexually active females of childbearing potential participating in the study must agree to use a medically-acceptable method of contraception while receiving study product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses. Exception: Sexually inactive females of childbearing potential are not required to practice a reliable method of contraception and may be enrolled at the investigator's discretion, provided that they understand the possible risks involved in getting pregnant during the study and are counseled to remain sexually inactive for the duration of the study or to practice a reliable method of contraception if becoming sexually active during the study.
Subjects must sign a written informed consent.
Subjects must sign a photo release form.
Exclusion Criteria:
Any systemic treatment for hair loss within the last 6 months including hormonal therapy for peri-menopausal females.
Concurrent therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study.
Subjects under current treatments in study area with light therapy, microneedling, Platelet-rich Plasma, prostaglandin analogues, ketoconazole, hair transplant or any method deemed unacceptable by the investigator.
Any history of drug interaction, such as, aminoglycoside antibiotics, penicillamine, quinine and calcium channel blockers
Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products.
History of allergic reaction to similar products (Botox® or Dysport®)
Albumin sensitivity (allergy to eggs)
Subjects with any signs of infection at the injection sites
Active cold or sinus infection
Any dermatologic or systemic disorder, which in the investigator's opinion, may interfere with the treatment. Examples of such disorders include neuromuscular disorders, hypertrophic scarring, keloidal scarring, bleeding disorders, subjects on immunosuppressive medications, and lupus erythematosus.
Subjects who are pregnant, breast feeding or planning a pregnancy during the study period.
Subjects who are unwilling or unable to comply with the requirements of the protocol.
Participation in another research study (currently or within the last 30 days).
All volunteers unwilling to sign the consent forms after being informed of their obligations and risks that they might encounter as a participant in this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mona Selim, M.D.
Phone
6513646289
Email
mona.selim@unitedskin.com
First Name & Middle Initial & Last Name or Official Title & Degree
Mona Selim, M.D.
Phone
6513646289
Email
mona.selim@uniteskin.com
Facility Information:
Facility Name
ZelSkin and Laser Specialists
City
Edina
State/Province
Minnesota
ZIP/Postal Code
55424
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mona Selim, M.D.
Phone
651-364-6289
Email
mona.selim@unitedskin.com
First Name & Middle Initial & Last Name & Degree
Mona Selim, M.D.
Phone
6513646289
Email
mona.selim@unitedskin.com
First Name & Middle Initial & Last Name & Degree
Brian D Zelickson, MD
12. IPD Sharing Statement
Citations:
PubMed Identifier
30394586
Citation
Russo PM, Fino E, Mancini C, Mazzetti M, Starace M, Piraccini BM. HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety. J Eur Acad Dermatol Venereol. 2019 Mar;33(3):608-611. doi: 10.1111/jdv.15327. Epub 2018 Dec 2.
Results Reference
background
PubMed Identifier
10583042
Citation
Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol. 1999 Sep;141(3):398-405. doi: 10.1046/j.1365-2133.1999.03030.x.
Results Reference
background
PubMed Identifier
15818439
Citation
Bienova M, Kucerova R, Fiuraskova M, Hajduch M, Kolar Z. Androgenetic alopecia and current methods of treatment. Acta Dermatovenerol Alp Pannonica Adriat. 2005 Mar;14(1):5-8.
Results Reference
background
PubMed Identifier
11231244
Citation
Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001 Jan;27(1):53-4.
Results Reference
background
PubMed Identifier
31677111
Citation
Starace M, Orlando G, Alessandrini A, Piraccini BM. Female Androgenetic Alopecia: An Update on Diagnosis and Management. Am J Clin Dermatol. 2020 Feb;21(1):69-84. doi: 10.1007/s40257-019-00479-x.
Results Reference
background
PubMed Identifier
23016593
Citation
Inui S, Itami S. Androgen actions on the human hair follicle: perspectives. Exp Dermatol. 2013 Mar;22(3):168-71. doi: 10.1111/exd.12024. Epub 2012 Sep 28.
Results Reference
background
PubMed Identifier
26375223
Citation
Ramos PM, Miot HA. Female Pattern Hair Loss: a clinical and pathophysiological review. An Bras Dermatol. 2015 Jul-Aug;90(4):529-43. doi: 10.1590/abd1806-4841.20153370.
Results Reference
background
PubMed Identifier
20128792
Citation
Cousen P, Messenger A. Female pattern hair loss in complete androgen insensitivity syndrome. Br J Dermatol. 2010 May;162(5):1135-7. doi: 10.1111/j.1365-2133.2010.09661.x. Epub 2010 Feb 1.
Results Reference
background
PubMed Identifier
22626036
Citation
Sinclair R. Winding the clock back on female androgenetic alopecia. Br J Dermatol. 2012 Jun;166(6):1157-8. doi: 10.1111/j.1365-2133.2012.10934.x. No abstract available.
Results Reference
background
PubMed Identifier
11425637
Citation
Cotsarelis G, Millar SE. Towards a molecular understanding of hair loss and its treatment. Trends Mol Med. 2001 Jul;7(7):293-301. doi: 10.1016/s1471-4914(01)02027-5.
Results Reference
background
PubMed Identifier
8628793
Citation
Goldman BE, Fisher DM, Ringler SL. Transcutaneous PO2 of the scalp in male pattern baldness: a new piece to the puzzle. Plast Reconstr Surg. 1996 May;97(6):1109-16; discussion 1117. doi: 10.1097/00006534-199605000-00003.
Results Reference
background
PubMed Identifier
27163333
Citation
Ramos PM, Brianezi G, Martins AC, da Silva MG, Marques ME, Miot HA. Apoptosis in follicles of individuals with female pattern hair loss is associated with perifollicular microinflammation. Int J Cosmet Sci. 2016 Dec;38(6):651-654. doi: 10.1111/ics.12341. Epub 2016 Jun 1.
Results Reference
background
PubMed Identifier
22440736
Citation
Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, Loy DE, Zhao T, Blatt HB, Stanton DC, Carrasco L, Ahluwalia G, Fischer SM, FitzGerald GA, Cotsarelis G. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012 Mar 21;4(126):126ra34. doi: 10.1126/scitranslmed.3003122.
Results Reference
background
PubMed Identifier
1390168
Citation
Jaworsky C, Kligman AM, Murphy GF. Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. Br J Dermatol. 1992 Sep;127(3):239-46. doi: 10.1111/j.1365-2133.1992.tb00121.x.
Results Reference
background
PubMed Identifier
27081243
Citation
Gupta M, Mysore V. Classifications of Patterned Hair Loss: A Review. J Cutan Aesthet Surg. 2016 Jan-Mar;9(1):3-12. doi: 10.4103/0974-2077.178536.
Results Reference
background
PubMed Identifier
14819896
Citation
HAMILTON JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951 Mar;53(3):708-28. doi: 10.1111/j.1749-6632.1951.tb31971.x. No abstract available.
Results Reference
background
PubMed Identifier
1188424
Citation
Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975 Nov;68(11):1359-65. doi: 10.1097/00007611-197511000-00009.
Results Reference
background
PubMed Identifier
921894
Citation
Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977 Sep;97(3):247-54. doi: 10.1111/j.1365-2133.1977.tb15179.x.
Results Reference
background
PubMed Identifier
9922024
Citation
Olsen EA. The midline part: an important physical clue to the clinical diagnosis of androgenetic alopecia in women. J Am Acad Dermatol. 1999 Jan;40(1):106-9. doi: 10.1016/s0190-9622(99)70539-6. No abstract available.
Results Reference
background
PubMed Identifier
30565210
Citation
Kasprzak M, Sicinska J, Sinclair R. The Trichoscopy Derived Sinclair Scale: Enhancing visual assessment through quantitative trichoscopy. Australas J Dermatol. 2019 May;60(2):134-136. doi: 10.1111/ajd.12964. Epub 2018 Dec 18.
Results Reference
background
PubMed Identifier
15280836
Citation
Sinclair R, Jolley D, Mallari R, Magee J. The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. J Am Acad Dermatol. 2004 Aug;51(2):189-99. doi: 10.1016/s0190-9622(03)00045-8.
Results Reference
background
PubMed Identifier
18044135
Citation
Dinh QQ, Sinclair R. Female pattern hair loss: current treatment concepts. Clin Interv Aging. 2007;2(2):189-99.
Results Reference
background
PubMed Identifier
27114071
Citation
Afifi L, Maranda EL, Zarei M, Delcanto GM, Falto-Aizpurua L, Kluijfhout WP, Jimenez JJ. Low-level laser therapy as a treatment for androgenetic alopecia. Lasers Surg Med. 2017 Jan;49(1):27-39. doi: 10.1002/lsm.22512. Epub 2016 Apr 25.
Results Reference
background
PubMed Identifier
24474647
Citation
Jimenez JJ, Wikramanayake TC, Bergfeld W, Hordinsky M, Hickman JG, Hamblin MR, Schachner LA. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol. 2014 Apr;15(2):115-27. doi: 10.1007/s40257-013-0060-6.
Results Reference
background
PubMed Identifier
29707872
Citation
Starace M, Alessandrini A, D'Acunto C, Melandri D, Bruni F, Patrizi A, Piraccini BM. Platelet-rich plasma on female androgenetic alopecia: Tested on 10 patients. J Cosmet Dermatol. 2019 Feb;18(1):59-64. doi: 10.1111/jocd.12550. Epub 2018 Apr 30.
Results Reference
background
PubMed Identifier
29440850
Citation
Giordano S, Romeo M, di Summa P, Salval A, Lankinen P. A Meta-analysis On Evidence Of Platelet-rich Plasma for Androgenetic Alopecia. Int J Trichology. 2018 Jan-Feb;10(1):1-10. doi: 10.4103/ijt.ijt_74_16.
Results Reference
background
PubMed Identifier
29403190
Citation
Singh S, Neema S, Vasudevan B. A Pilot Study to Evaluate Effectiveness of Botulinum Toxin in Treatment of Androgenetic Alopecia in Males. J Cutan Aesthet Surg. 2017 Jul-Sep;10(3):163-167. doi: 10.4103/JCAS.JCAS_77_17.
Results Reference
background
PubMed Identifier
32802833
Citation
Zhou Y, Yu S, Zhao J, Feng X, Zhang M, Zhao Z. Effectiveness and Safety of Botulinum Toxin Type A in the Treatment of Androgenetic Alopecia. Biomed Res Int. 2020 Aug 4;2020:1501893. doi: 10.1155/2020/1501893. eCollection 2020.
Results Reference
background
PubMed Identifier
33894053
Citation
Melo DF, Ramos PM, Antelo DAP, Machado CJ, Barcaui CB. Is there a rationale for the use of botulinum toxin in the treatment of Androgenetic Alopecia? J Cosmet Dermatol. 2021 Jul;20(7):2093-2095. doi: 10.1111/jocd.14177. Epub 2021 May 3. No abstract available.
Results Reference
background
PubMed Identifier
30566260
Citation
Zhang L, Yu Q, Wang Y, Ma Y, Shi Y, Li X. A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients. Dermatol Ther. 2019 Jul;32(4):e12785. doi: 10.1111/dth.12785. Epub 2019 Jan 8. No abstract available.
Results Reference
background
PubMed Identifier
14576664
Citation
Unger WP, Unger RH. Hair transplanting: an important but often forgotten treatment for female pattern hair loss. J Am Acad Dermatol. 2003 Nov;49(5):853-60. doi: 10.1016/s0190-9622(03)01568-8.
Results Reference
background
PubMed Identifier
29178529
Citation
Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, Trakatelli M, Tosti A, Del Marmol V, Piraccini BM, Nast A, Blume-Peytavi U. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):11-22. doi: 10.1111/jdv.14624. Epub 2017 Nov 27.
Results Reference
background
PubMed Identifier
33603602
Citation
Witmanowski H, Blochowiak K. The whole truth about botulinum toxin - a review. Postepy Dermatol Alergol. 2020 Dec;37(6):853-861. doi: 10.5114/ada.2019.82795. Epub 2019 Feb 5.
Results Reference
background
PubMed Identifier
33562846
Citation
Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review. Toxins (Basel). 2021 Feb 5;13(2):120. doi: 10.3390/toxins13020120.
Results Reference
background
PubMed Identifier
20927234
Citation
Rakowska A, Slowinska M, Kowalska-Oledzka E, Olszewska M, Rudnicka L. Dermoscopy in female androgenic alopecia: method standardization and diagnostic criteria. Int J Trichology. 2009 Jul;1(2):123-30. doi: 10.4103/0974-7753.58555.
Results Reference
background
Learn more about this trial
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
We'll reach out to this number within 24 hrs